Lithium (Eskalith® and others), a naturally occurring salt, has been used for various medical purposes since the 1800s. Initially, it was given to patients who suffered from urinary calculi and gout. Later, it was combined with bromides and used as a sedative. In 1949, Cade observed that lithium calmed agitated psychotic patients: ten manic patients responded, six schizophrenic and chronically depressed psychotic patients did not, and one patient’s symptoms reappeared after lithium was stopped.1 During this same period, lithium was introduced in the United States as a salt substitute for cardiac patients, but it caused numerous toxic reactions and several deaths. Thus, even with the emergence of convincing evidence that lithium was safe and effective in manic depressive illness, it was not accepted in the United States until 1970.
KeywordsBipolar Disorder Mood Disorder Antipsychotic Drug Neuroleptic Malignant Syndrome Antipsychotic Agent
Unable to display preview. Download preview PDF.
- 1.Cade J. F. J.: Lithium salts in the treatment of psychotic excitement. Med J Aust 11:349–352, 1949.Google Scholar
- 8.American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd ed revised (DSM-IIIR). Washington, American Psychiatric Association, 1987.Google Scholar
- 11.Winokur G., Clayton P. J., Reich T.: Manic Depressive Disease. St. Louis, C. V. Mosby, 1969.Google Scholar
- 12.Weissman M. M., Leaf P. J., Livingston B. M., et al.: The epidemiology of dysthymia in the community: Rates, risks, comorbidity and treatment. 140th Annual Meeting of the American Psychiatric Association, Chicago, American Psychiatric Association, 1987.Google Scholar
- 13.Medical Practice Project: A State-of-the-Science Report for the Office of the Assistant Secretary for the U. S. Department of Health, Education and Welfare. Baltimore, Policy Research, 1979.Google Scholar
- 17.Fieve R. R.: Overview of therapeutic and prophylactic trials with lithium in psychiatric patients, in Gershon S., Shopsin B. (eds): Lithium. Its Role in Psychiatric Research and Treatment. New York, Plenum Press, 1973, p 336.Google Scholar
- 19.Cooper T. B.: Pharmacokinetics of lithium, in Meltzer H. Y. (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 1365–1376.Google Scholar
- 24.Mellerup E. T., Plenge P., Rafaelson O. J. : Renal and other controversial adverse effects of lithium, in Meltzer H. Y. (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 1443–1448.Google Scholar
- 25.Gelenberg A. J.: Lithium-induced polyuria: Approaches to management. Biol Ther Psychiatry Newslett 6:17–19, 1983.Google Scholar
- 27.Gelenberg A. J.: Lithium and the nephrotic syndrome. Biol Ther Psychiatry 12:24, 1989.Google Scholar
- 28.Shopsin B., Gershon S.: Pharmacology-toxicology of the lithium ion, in Gershon S., Shopsin B. (eds): Lithium: Its Role in Psychiatric Research and Treatment. New York, Plenum Press, 1973, pp 107–146.Google Scholar
- 32.Worthley L. J. C.: Lithium toxicity and refractory cardiac arrhythmia treated with intravenous magnesium. Anesth Intens Care 2:357–360, 1974.Google Scholar
- 33.Jefferson J. W., Greist J. H. : Adverse reactions—neurological tremor, in Jefferson, J. W., Greist, J. H. (eds): Primer of Lithium Therapy. Baltimore, Williams & Wilkins, 1977, pp 139–150.Google Scholar